Phase I/II clinical study of pulsed paclitaxel radiosensitization for thoracic malignancy: A therapeutic approach on the basis of preclinical research of human cancer cell lines

Clinical Cancer Research

Volumn 9, Issue 3, 2003, Pages 969-975

  Chen, Yuhchyau ^a,b   Pandya, Kishan ^a   Keng, Peter C ^a   Johnstone, David ^a   Li, Jigang ^a   Lee, Yi Jang ^a   Smudzin, Therese ^a   Okunieff, Paul ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Box 647 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ESOPHAGITIS; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

APOPTOSIS; CELL CYCLE; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; G2 PHASE; HUMANS; MAXIMUM TOLERATED DOSE; MITOSIS; PACLITAXEL; RADIATION-SENSITIZING AGENTS; THORACIC NEOPLASMS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR CELLS, CULTURED;

EID: 0037342884     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Schiff, P. B., and Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA, 77: 1561-1565, 1980.
2. Parness, J., and Horwitz, S. B. Taxol binds to polymerized tubulin in vitro. J. Cell Biol., 91: 479-487, 1981.
3. Manfredi, J. J., Parness, J., and Horwitz, S. B. Taxol binds to cellular microtubules. J. Cell Biol., 94: 688-696, 1982.
4. Kumar, N. Taxol-induced polymerization of purified tubulin. Mechanism of action. J. Biol., Chem., 256: 10435-10441, 1981.
5. Rowinsky, E. K., Donehower, R. C., Jones, R. J., and Tucker, R. W. Microtubule changes and cytotoxicity in leukemia cell lines treated with Taxol. Cancer Res., 48: 4093-4100, 1988.
6. Milas, L., Hunter, N. R., Kurdoglu, B., Mason, K. A., Meyn, R. E., Stephens, L. C., and Peters, L. J. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with Taxol. Cancer Chemother. Pharmacol., 35: 297-303, 1995.
7. Milross, C. G., Mason, K. A., Hunter, N. R., Chung, W. K., Peter, L. J., and Milas, L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J. Natl. Cancer Inst. (Bethesda), 88: 1308-1314, 1996.
8. Jordan, M. A., Wendell, K., Gardiner, S., Derry, W. B., Copp, H., and Wilson, L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel results in abnormal mitotic exit and apoptotic cell death. Cancer Res., 56: 816-825, 1996.
9. Pukkinen, J. O., Elomaa, L., Joensuu, H., Martikainen, P., Servomaa, K., and Crenman, R. Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer. J. Cancer Res. Clin. Oncol., 122: 214-218, 1996.
10. Sinclair, W. K., and Morton, R. A. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat. Res., 29: 450-474, 1966.
11. Tishler, R. B., Geard, C. R., Hall, E. J., and Schiff, P. B. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res., 52: 3495-3497, 1992.
12. Geard, C. R., Jones, J. M., and Schiff, P. B. Taxol and radiation. J. Natl. Cancer Inst. Mono., 15: 89-94, 1993.
13. Rodriguez, M., Sevin, B. U., Perras, J., Nguyen, H. N., Pham, C., Steren, A. J., Koechli, O. R., and Averette, H. E. Paclitaxel: A radiation sensitizer of human cervical cancer cells. Gyn. Oncol., 57: 165-169, 1995.
14. Lokeshwar, B. L., Ferrell, S. M., and Block, N. L. Enhancement of radiation response of prostatic carcinoma by Taxol: therapeutic potential for late-stage malignancy. Anticancer Res., 15: 93-98, 1995.
15. Elomaa, L., Joensuu, H., Kulmala, J., Klemi, P., and Grenman, R. Squamous cell carcinoma is highly sensitive to Taxol, a possible new radiation sensitizer. Acta Otolaryngol., 115: 340-344, 1995.
16. Choy, H., Rodriguez, F. F., Koester, S., Hilsenbeck, S., and von Hoff, D. D. Investigation of Taxol as a potential radiation sensitizer. Cancer (Phila.), 71: 3774-3778, 1993.
17. Choy, H., Safran, H., Akerley, W., Graziano, S. L., Bogart, J. A., and Cole, B. F. Phase II trial weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin. Cancer Res., 4: 1931-1936, 1998.
18. Lau, D., Ryu, J., Gandara, D., Morgan, R., Doroshow, J., Wilder, R., and Leigh, B. Concurrent twice-weekly paclitaxel and thoracic irradiation for stage III non-small cell lung cancer. Semin. Radiat. Oncol., 9: 117-120, 1999.
19. Rosenthal, D. I., Okani, O., Corak, J., Kavanaugh, D., Kamen, B., Vuitch, F. M., Gazdar, A. F., Greiner, J., Frenkel, E. F., and Carbone, D. P. Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a Phase I study. Semin. Oncol., 24: s12096-s12100, 1997.
20. Kirkbride, P., Gelmon, K., and Eisenhauer, E. Paclitaxel and concurrent radiotherapy in locally advanced non-small cell lung cancer: the Canadian experience. Semin. Radiat. Oncol., 9: 102-107, 1999.
21. Formenti, S. C., Symmans, W. F., Volm, M., Skinner, K., Cohen, D., Spicer, D., and Danenberg, P. V. Concurrent paclitaxel and radiation therapy for breast cancer. Semin. Radiat. Oncol., 9: 34-42, 1999.
22. Choy, H., Yee, L., and Cole, B. F. Combined-modality therapy for advanced non-small cell lung cancer: Paclitaxel and thoracic irradiation. Semin. Oncol., 22: 38-44, 1995.
23. Aisner, J., Belani, C. P., Kearns, C., Conley, B., Hiponia, D., Engstrom, C., Zuhowski, E., and Egorin, M. J. Feasibility and pharmacokinetic of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer. Semin. Oncol., 22: 17-21, 1995.
24. Havemann, K., Wolf, M., George, C., Faoro, C., Pfab, R., and Diergarten, K. Paclitaxel and simultaneous radiation in the treatment of stage III A/B non-small cell lung cancer. Semin. Oncol., 22: 19-22, 1995.
25. Antonia, S. J., Wagner, H., Williams, C., Alberts, M., Hubbell, D., Robinson, L., Hilstro, J., and Ruckdeschel, J. C. Concurrent paclitaxel/ cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung. Semin. Oncol., 22: 34-37, 1995.
26. Greco, F. A., Stroup, S. L., Gray, J. R., and Hainsworth, J. D. Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J. Clin. Oncol., 14: 1642-1648, 1996.
27. Common Toxicity Criteria, version 2.0, National Institute of Health, National Cancer Institute, pp. 25-26 and 54-57. Reprinted September 1999.
28. Cox, J. D., Stetz, J., and Pajak, T. F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int. J. Radiat. Oncol. Biol. Phys., 31: 1341-1346, 1995.
29. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
30. Schaake-Koning, C., van den Bogaert, W., Dalesio, O., Festen, J., Hoogenhout, J., van Houtte, P., Kirkpatrick, A., Koolen, M., Maat, B., and Nijs, A. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N. Engl. J. Med., 326: 524-530, 1992.
31. Furuse, K., Fukuoka, M., Kawahara, M., Nishikawa, H., Takada, Y., Kudoh, S., Katagami, N., and Ariyoshi, Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J. Clin. Oncol., 17: 2692-2699, 1999.
32. Dillman, R. O., Seagren, S. L., Propert, K. J., Guerra, J., Eaton, W. L., Perry, M. C., Carey, R. W., Frei, E. F., III, and Green, M. R. A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non-small cell lung cancer. N. Engl. J. Med., 323: 940-945, 1990.
33. Arriagada, R., le Chevalier, T., Quoix, E., Ruffie, P., de Cremous, H., Douillard, J-Y., Tarayre, M., Pignon, J-P., and Laplanche, A. ASTRO plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma - a randomized study of 353 patients. Int. J. Radiat. Oncol. Biol. Phys., 20: 1183-1190, 1991.
34. Sause, W., Kolesar, P., Taylor, S. I. V., Johnson, D., Livingston, R., Komaki, R., Emami, B., Curran, W., Byhardt, R., Dar, A. R., and Turrisi, A. Final results of Phase III trial in regionally advanced unresectable non-small cell lung cancer. Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest, 117: 358-364, 2000.
35. Morton, R. F., Jett, J. R., McGinnis, W. L., Earle, J. D., Therneau, T. M., Krook, J. E., Elliott, T. E., Mailliard, J. A., Nelimark, R. A., Maksymiuk, A. W., Drummond, R. G., Laurie, J. A., Kugler, J. W., and Anderson, R. T. Thoracic radiation therapy alone compared with combined chemotherapy for locally unresectable non-small cell lung cancer. Ann. Int. Med., 115: 681-686, 1991.
36. Curran, W. J., Jr., Scott, C., Langer, C., Komaki, R., Lee, J., Hauser, S., Movsas, B., Wasserman, T. H., Rosenthal, S., Byhardt, R., Sause, W., and Cox, J. Phase III comparison of sequential versus concurrent chemoradiation for PTS with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 19: 484a, 2000.
37. Milas, L., Hunter, N., Mason, K. A., Milross, C., and Peters, L. Tumor re-oxygenation as a mechanism of Taxol-induced enhancement of tumor radioresponse. Acta Oncol., 34: 409-412, 1995.
38. Browder, T., Butterfield, C. E., Kraling, B. M., Shi, B., Marshall, B., O'Reilly, M. S., and Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 60: 1878-1886, 2000.
39. Boehm, T., Flokman, J., Browder, T., and O'Reilly. M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390: 404-407, 1997.